Vertex Pharmaceuticals Incorporated (FRA:VX1)
391.85
+0.45 (0.11%)
Last updated: May 13, 2025
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B USD in the quarter ending March 31, 2025, with 2.96% growth. This brings the company's revenue in the last twelve months to $11.10B, up 8.98% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.10B
Revenue Growth
+8.98%
P/S Ratio
9.67
Revenue / Employee
$1.82M
Employees
6,100
Market Cap
99.29B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 76.54B |
Deutsche Telekom AG | 118.43B |
Allianz SE | 107.35B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.15B |
Rheinmetall AG | 10.48B |
Siemens Energy AG | 37.44B |
Siemens Healthineers AG | 23.14B |
Vertex Pharmaceuticals News
- 7 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Vertex misses on both lines in Q1 as 2025 revenue forecast narrowed - Seeking Alpha
- 8 days ago - Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance - Benzinga
- 8 days ago - Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug - Reuters
- 8 days ago - Vertex Pharmaceuticals Non-GAAP EPS of $4.06 misses by $0.23, revenue of $2.77B misses by $90M - Seeking Alpha
- 8 days ago - Vertex Reports First Quarter 2025 Financial Results - Business Wire
- 8 days ago - Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum? - Benzinga
- 8 days ago - Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum? - Benzinga